The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The trial will enroll up to 42 patients in Finland across four cohorts
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The protections extend through at least 2035, with the potential for further extensions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
